登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C23H20N4O3 · HCl
化学文摘社编号:
分子量:
436.89
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
InChI key
OQCLKJREASBKNO-UHFFFAOYSA-N
SMILES string
Cl.COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC
InChI
1S/C23H20N4O3.ClH/c1-29-20-12-18-19(13-21(20)30-2)24-14-25-22(18)26-16-8-10-17(11-9-16)27-23(28)15-6-4-3-5-7-15;/h3-14H,1-2H3,(H,27,28)(H,24,25,26);1H
assay
≥98% (HPLC)
form
solid
color
yellow
solubility
H2O: <2 mg/mL, DMSO: ~2.4 mg/mL (with warming up to 60°C for 1 minute)
originator
AstraZeneca
storage temp.
2-8°C
Biochem/physiol Actions
Aurora Kinase Inhibitor
Features and Benefits
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Nicola M Heron et al.
Bioorganic & medicinal chemistry letters, 16(5), 1320-1323 (2005-12-13)
A novel series of 5-aminopyrimidinyl quinazolines has been developed from anilino-quinazoline 1, which was identified in a high throughput screen for Aurora A. Introduction of the pyrimidine ring and optimisation of the substituents both on this ring and at the
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持